OPT 302

Drug Profile

OPT 302

Alternative Names: OPT-302; soluble VEGFR-3; VGX 300

Latest Information Update: 07 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vegenics
  • Developer Opthea
  • Class Eye disorder therapies
  • Mechanism of Action Vascular endothelial growth factor C inhibitors; Vascular endothelial growth factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration

Most Recent Events

  • 09 Aug 2017 Opthea plans a phase IIb trial for Wet age-related macular degeneration (Treatment-naive) in USA, United Kingdom and European Union (Intravitreous, Injection) in the second half of 2017
  • 09 Aug 2017 Opthea plans a phase IIa trial in Diabetic macular oedema and Wet age-related macular degeneration (Treatment-experienced) in the second half of 2017
  • 06 Jul 2017 Opthea has a method of use patent protection for OPT 302 administered alone or in combination for disorders associated with neovascularisation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top